Lenacapavir for HIV prevention is a long-acting injectable PrEP option. The US FDA approved it for reducing the risk of sexually acquired HIV in eligible adults and adolescents in June 2025, and WHO recommended it as an additional prevention choice in July 2025.
This is general information and does not replace an individual PrEP assessment. Do not buy, start, stop, share, or change HIV prevention medicine on your own. Approval, availability, eligibility, and cost can differ by country and health system.
What is lenacapavir for HIV prevention?
Lenacapavir is a long-acting medicine offered as PrEP to people who do not have HIV and may benefit from additional prevention. Its long duration may help people who find daily tablets difficult because of routine, privacy, stigma, or access.
Does it completely prevent HIV?
No prevention method should be described as a guarantee for one person. Clinical studies found very high protection when the medicine and follow-up were used as intended, but HIV testing, timely appointments, and correct continuation remain essential.
What must happen before starting?
- Confirm that the person does not have HIV
- Discuss the most recent possible exposure and any PEP or PrEP use
- Review medicines, supplements, allergies, pregnancy, and health history
- Confirm that the product is approved and available in the local service
- Make a written plan for future injections and HIV testing
Why does follow-up matter?
Long-acting medicine remains in the body after an injection. Late follow-up or undiagnosed HIV can create safety concerns, including drug resistance. Contact the clinic early if an appointment may be missed; do not replace or extend protection with another product without advice.
What does lenacapavir not prevent?
It does not prevent syphilis, gonorrhoea, chlamydia, herpes, HPV, hepatitis, or pregnancy. Condoms, STI testing, vaccination, contraception, and other options can be combined according to personal goals.
Read more about who may consider PrEP and HIV self-testing and confirmation.
Frequently asked questions
Is lenacapavir available everywhere?
No. Approval and implementation vary. Ask a local PrEP service rather than assuming US approval means immediate local access.
Can it be used after a recent exposure?
PrEP is not a substitute for urgent HIV PEP assessment after a recent possible exposure.
Can someone stop attending after an injection?
No. HIV testing and planned follow-up remain important because the medicine is long acting.
Summary
Lenacapavir adds a highly effective, long-acting PrEP choice, but it is not a universal or automatic option. Safe use begins with an HIV-negative result, an individual assessment, reliable follow-up, and confirmation of local availability.
